Dr. Dorff on the Continued Investigation of Upfront Chemotherapy in mHSPC
March 10th 2023Tanya Dorff, MD, discusses key data supporting the use of intensified triplet regimens in metastatic hormone-sensitive prostate cancer, and remaining questions regarding the role of chemotherapy agents in these combinations.
Read More
Practical Considerations in Selecting Therapy for Metastatic CRPC
Closing out their discussion on prostate cancer, expert panelists highlight which factors best inform selection of therapy for patients with mCRPC.
Read More
What is the Role of 177Lu-PSMA-617 in Metastatic CRPC?
Panelists share insight on 177Lu-PSMA-617 and consider where it might fit into the treatment paradigm for metastatic castration-resistant prostate cancer.
Read More
Metastatic CRPC: Practical Selection and Use of PARP Inhibitors
Expert perspectives on how PARP inhibition will fit into the real-world management of patients with metastatic castration-resistant prostate cancer.
Read More
An Overview of PARP Inhibition in Metastatic CRPC
Focusing on the advent of PARP inhibitors in metastatic castration-resistant prostate cancer, genitourinary cancer specialists provide an overview of clinical trials and agents in this setting.
Read More
PTEN Loss in mCRPC: Caution Surrounding mTOR, PI3K, and AKT Inhibition
Panelists share caution toward use of mTOR-, PI3K-, and AKT-targeted therapies in the setting of PTEN loss in metastatic CRPC.
Read More
Therapy Overview: Sequencing Agents in Patients With Metastatic CRPC
A comprehensive review of available agents in the setting of metastatic CRPC, with discussion of optimal sequencing in later lines of therapy.
Read More
Metastatic Castration-Resistant Prostate Cancer: Optimal Imaging Strategies
Expert oncologists define appropriate imaging strategies, conventional and novel, in patients with metastatic castration-resistant prostate cancer.
Read More
Clinical Scenario 3: A 76-Year-Old With Metastatic CRPC
Shared insight on a clinical scenario of metastatic castration-resistant prostate cancer managed with androgen-deprivation therapy and docetaxel.
Read More
Addressing Unmet Needs in Nonmetastatic CRPC
Before closing out their second module, panelists highlight remaining unmet needs in the setting of nonmetastatic castration-resistant prostate cancer.
Read More
Selecting Among Available AR Inhibitors in Nonmetastatic CPRC
A comprehensive discussion on factors that inform treatment selection of available AR-targeted therapy for patients with nonmetastatic CRPC.
Read More
Optimizing Management of nmCRPC: Patient Monitoring and Initiating Therapy
Expert perspectives on monitoring patients with nonmetastatic castration-resistant prostate cancer and deciding when to initiate systemic therapy.
Read More
Clinical Scenario 2: A 64-Year-Old Man With nmCRPC
Shared insight on a clinical scenario of a patient with nonmetastatic castration-resistant prostate cancer who was treated with prostatectomy and adjuvant therapy.
Read More
Improving Patient Monitoring in the Setting of Metastatic HSPC
Closing out their discussion on a clinical scenario of metastatic HSPC, expert panelists consider optimal patient monitoring strategies and novel imaging.
Read More